After nearly a century of being defined by ovarian cysts that often had little to do with its systemic effects, the condition long known as polycystic ovary syndrome has been formally renamed. An initiative led by Australian endocrinologist Helena Teede, published in The Lancet, introduces the term polyendocrine metabolic ovarian syndrome, or PMOS. The change aims to correct a fundamental misunderstanding: what surgeons in the 1920s mistook for cysts are now understood as a symptom of a far broader endocrine and metabolic disorder that affects one in eight women globally—rising to one in six among Indigenous Australian women—and is linked to elevated risks of Type 2 diabetes, cardiovascular disease, and infertility.

Viewed from Sydney, where Teede leads the Monash University research group, the rebranding is the culmination of decades of evidence that the original name misled both patients and clinicians. The term PCOS, by fixating on the ovaries, obscured a condition that also drives insulin resistance, weight gain, acne, and mood disorders. In New Delhi, medical commentators have noted that the new name will help dismantle the stigma and fragmentation of care that have long plagued diagnosis, while in São Paulo, specialists have welcomed the clarity, arguing that the previous nomenclature contributed to delayed recognition and inadequate treatment. The shift, endorsed by major international endocrinology societies, is seen as a necessary correction to a name that was always a convenient fiction.

Yet the renaming is only the beginning. Clinicians in Rome and Buenos Aires point out that PMOS often coexists with other underdiagnosed conditions such as endometriosis—a disease that, as experts in Argentina and Italy stress, is frequently mistaken for severe menstrual pain and can compound reproductive and metabolic complications. Meanwhile, persistent back pain during pregnancy, as discussed in Tehran, and migraines during perimenopause, highlighted in reports from Los Andes, underscore a broader pattern: women’s pain and hormonal disorders are too often normalised or attributed to benign causes. The rebranding of PCOS to PMOS is therefore part of a larger, overdue reckoning with the systemic dismissal of women’s health complaints.

Looking ahead, the real test will be whether the new name translates into better clinical pathways. Analysts in London note that PMOS is not a simple relabelling but a call to integrate metabolic screening, cardiovascular monitoring, and mental health support alongside gynaecological care. In India, health authorities face the challenge of raising awareness in a population where diagnostic delays remain common. The name change, by aligning medical language with the biology of the condition, could accelerate research funding, public health policy, and patient education. What began as a surgical observation a century ago is finally being understood as the complex polyendocrine metabolic syndrome it always was—and the work of translating that understanding into everyday care has only just begun.